Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.

摘要: OBJECTIVE: Long-standing evidence indicates that Alzheimer's disease patients with behavioral symptoms have a worse prognosis and more rapid progression. The current retrospective analysis evaluated the efficacy safety of memantine in subpopulation exhibiting agitation/aggression or psychosis at baseline. METHOD: A pooled was conducted people from 3 large 6-month, randomized studies moderately severe to disease. effect placebo on these specific using Neuropsychiatric Inventory (NPI) subitem cluster agitation psychosis. Outcomes global, cognitive, functional measures were also analyzed. RESULTS: Sixty percent total patient group had baseline agitation/aggression, delusions, hallucinations NPI. At both 12 24/28 weeks, there significant treatment advantage for over proportion showing improvement defined neuropsychiatric symptom (55.6% vs. 44.4% week 12, p = .008; 58.0% 44.8% 24/28, .002) specifically (55.3% 43.1% .011; 61.0% 45.0% < .001). Placebo-treated this population demonstrated an accelerated progression global (Clinician's Interview-Based Impression Change Plus Caregiver Input), cognitive (Severe Impairment Battery), (Alzheimer Disease Cooperative Study Activities Daily Living 19-item scale) outcomes, but conferred statistically benefit all measures. Tolerability remained good, fewer memantine-treated than placebo-treated withdrew due adverse events. CONCLUSIONS: This post hoc provides important placebo-controlled trials may be safe effective psychosis, who are otherwise prone Memantine provided benefits functional, outcomes their agitation/aggression.